CFA
ALNY icon

Carroll Financial Associates’s Alnylam Pharmaceuticals ALNY Stock Holding History

Carroll Financial Associates’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-41
Closed -$7K – 1606
2021
Q3 		$7K Buy
41
+7
+21% +$1.31K ﹤0.01% 1299
2021
Q2 		$5K Hold
34
– – ﹤0.01% 1423
2021
Q1 		$4K Buy
+34
New +$5.12K ﹤0.01% 1390

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Carroll Financial Associates's ALNY Position: Q4 2021 in Review

Carroll Financial Associates sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2021, closing a stake of 41 shares — an estimated $7K sold.

Carroll Financial Associates first reported a position in ALNY in Q1 2021 and held it in 3 quarters. The position peaked at $7K in Q3 2021. 434 funds tracked by Wall St. Rank hold ALNY as of Q4 2021.

  • Carroll Financial Associates reported no remaining Alnylam Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Carroll Financial Associates sold 41 Alnylam Pharmaceuticals shares in Q4 2021, an estimated $7K.
  • Carroll Financial Associates first reported a position in Alnylam Pharmaceuticals in Q1 2021 and held it in 3 quarters.
  • Carroll Financial Associates's Alnylam Pharmaceuticals position peaked at $7K in Q3 2021.
  • 434 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.